JATT vs. TCRX, KYTX, CRBU, STRO, NBTX, JMAC, IFRX, FTLF, CRBP, and MCRB
Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include TScan Therapeutics (TCRX), Kyverna Therapeutics (KYTX), Caribou Biosciences (CRBU), Sutro Biopharma (STRO), Nanobiotix (NBTX), Maxpro Capital Acquisition (JMAC), InflaRx (IFRX), FitLife Brands (FTLF), Corbus Pharmaceuticals (CRBP), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.
JATT Acquisition vs.
JATT Acquisition (NYSE:JATT) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations.
JATT Acquisition has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,188.88%. JATT Acquisition's return on equity of -49.58% beat TScan Therapeutics' return on equity.
TScan Therapeutics has a consensus target price of $11.25, suggesting a potential upside of 374.68%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than JATT Acquisition.
48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 2.8% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
JATT Acquisition has higher earnings, but lower revenue than TScan Therapeutics.
In the previous week, TScan Therapeutics had 2 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for TScan Therapeutics and 0 mentions for JATT Acquisition. TScan Therapeutics' average media sentiment score of 0.44 beat JATT Acquisition's score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.
TScan Therapeutics received 35 more outperform votes than JATT Acquisition when rated by MarketBeat users.
Summary
TScan Therapeutics beats JATT Acquisition on 8 of the 13 factors compared between the two stocks.
Get JATT Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
JATT Acquisition Competitors List
Related Companies and Tools
This page (NYSE:JATT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free JATT Stock Alerts